Company registration number 09277638 (England and Wales)
LIFT BIOSCIENCES LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
PAGES FOR FILING WITH REGISTRAR
LIFT BIOSCIENCES LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Statement of changes in equity
3
Notes to the financial statements
4 - 11
LIFT BIOSCIENCES LIMITED
BALANCE SHEET
AS AT
31 DECEMBER 2024
31 December 2024
- 1 -
2024
2023
Notes
£
£
£
£
Fixed assets
Intangible assets
5
11,289,178
7,940,886
Tangible assets
6
290,323
284,511
Investments
7
83,250
11,662,751
8,225,397
Current assets
Debtors
9
879,525
844,769
Cash at bank and in hand
3,596,546
1,483,231
4,476,071
2,328,000
Creditors: amounts falling due within one year
10
(587,792)
(4,692,435)
Net current assets/(liabilities)
3,888,279
(2,364,435)
Total assets less current liabilities
15,551,030
5,860,962
Creditors: amounts falling due after more than one year
11
(40,391)
(14,167)
Net assets
15,510,639
5,846,795
Capital and reserves
Called up share capital
13
380
249
Share premium account
16,707,187
6,508,532
Profit and loss reserves
(1,196,928)
(661,986)
Total equity
15,510,639
5,846,795
The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true
For the financial year ended 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.
The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
LIFT BIOSCIENCES LIMITED
BALANCE SHEET (CONTINUED)
AS AT
31 DECEMBER 2024
31 December 2024
- 2 -
The financial statements were approved by the board of directors and authorised for issue on 20 February 2025 and are signed on its behalf by:
Mr A W Blyth
Director
Company Registration No. 09277638
LIFT BIOSCIENCES LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2024
- 3 -
Share capital
Share premium account
Profit and loss reserves
Total
Notes
£
£
£
£
Balance at 1 January 2023
249
6,508,532
(335,156)
6,173,625
Year ended 31 December 2023:
Loss and total comprehensive income for the year
-
-
(326,830)
(326,830)
Balance at 31 December 2023
249
6,508,532
(661,986)
5,846,795
Year ended 31 December 2024:
Loss and total comprehensive income for the year
-
-
(534,942)
(534,942)
Issue of share capital
13
131
10,198,655
-
10,198,786
Balance at 31 December 2024
380
16,707,187
(1,196,928)
15,510,639
LIFT BIOSCIENCES LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 4 -
1
Accounting policies
Company information
Lift Biosciences Limited is a private company limited by shares incorporated in England and Wales. The registered office is London Bioscience Innovation Centre, 2 Royal College Street, London, NW1 0NH.
1.1
Accounting convention
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.
1.2
Research and development expenditure
Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated.
1.3
Intangible fixed assets other than goodwill
Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.
Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Patents & licences
10 years straight line
Development costs
10 years straight line
1.4
Tangible fixed assets
Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.
Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Plant and equipment
20% reducing balance
Fixtures and fittings
20% reducing balance
1.5
Fixed asset investments
Interests in subsidiaries are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.
A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.
LIFT BIOSCIENCES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 5 -
1.6
Impairment of fixed assets
At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.
1.7
Cash and cash equivalents
Cash and cash equivalents are basic financial assets and include cash in bank only.
1.8
Financial instruments
The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.
Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
Basic financial assets
Basic financial assets, which include other debtors, corporation tax recoverable and, cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.
Classification of financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
Basic financial liabilities
Basic financial liabilities, including trade creditors, bank loans, amounts owed to group undertakings, taxation and social security and other creditors, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
1.9
Equity instruments
Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs.
LIFT BIOSCIENCES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 6 -
1.10
Taxation
The tax expense represents the sum of the tax currently payable and deferred tax.
Current tax
The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.
Deferred tax
Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.
The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.
1.11
Employee benefits
The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of fixed assets.
1.12
Retirement benefits
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.
1.13
Leases
Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.
Assets held under finance leases are recognised as assets at the lower of the assets fair value at the date of inception and the present value of the minimum lease payments. The related liability is included in the balance sheet as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to profit or loss so as to produce a constant periodic rate of interest on the remaining balance of the liability.
1.14
Government grants
Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.
1.15
Foreign exchange
Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.
LIFT BIOSCIENCES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 7 -
2
Judgements and key sources of estimation uncertainty
In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.
3
Employees
The average monthly number of persons (including directors) employed by the company during the year was:
2024
2023
Number
Number
Total
16
16
4
Directors' remuneration
2024
2023
£
£
Remuneration paid to directors
225,862
178,997
5
Intangible fixed assets
Patents & licences
Development costs
Total
£
£
£
Cost
At 1 January 2024
433,311
7,524,451
7,957,762
Additions
243,246
3,116,494
3,359,740
At 31 December 2024
676,557
10,640,945
11,317,502
Amortisation and impairment
At 1 January 2024
16,876
16,876
Amortisation charged for the year
11,448
11,448
At 31 December 2024
28,324
28,324
Carrying amount
At 31 December 2024
648,233
10,640,945
11,289,178
At 31 December 2023
416,435
7,524,451
7,940,886
LIFT BIOSCIENCES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 8 -
6
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 January 2024
477,403
Additions
72,345
At 31 December 2024
549,748
Depreciation and impairment
At 1 January 2024
192,892
Depreciation charged in the year
66,533
At 31 December 2024
259,425
Carrying amount
At 31 December 2024
290,323
At 31 December 2023
284,511
The net carrying value of tangible fixed assets includes the following in respect of assets held under finance leases or hire purchase contracts.
2024
2023
£
£
Plant and machinery etc
61,234
61,234
-
The depreciation charge in respect of such assets amounted to £9,421 (2023 - £Nil).
LIFT BIOSCIENCES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 9 -
7
Fixed asset investments
2024
2023
£
£
Shares in group undertakings and participating interests
83,250
Movements in fixed asset investments
Shares in subsidiaries
£
Cost or valuation
At 1 January 2024
-
Additions
83,250
At 31 December 2024
83,250
Carrying amount
At 31 December 2024
83,250
At 31 December 2023
-
Shares in subsidiaries represent the company's 100% interest in the Ordinary share capital of Eolaiocht Bhitheach Lift Teoranta Limited, a company incorporated in the Republic of Ireland and 100% interest in the Common Stock of Lift Biosciences Inc, a company incorporated in the United States of America.
8
Subsidiaries
Details of the company's subsidiaries at 31 December 2024 are as follows:
Name of undertaking
Registered office
Class of
% Held
shares held
Direct
Eolaiocht Bhitheach Lift Teoranta Limited
Landscape House, Baldonnell Business Park, Baldonnell, Dublin, ireland, D22 P3K7
Ordinary
100.00
Lift Biosciences Inc
Resident Agents Inc, 8 The Green, Ste R, Dover, Kent, Delaware, 19901
Common Stock
100.00
9
Debtors
2024
2023
Amounts falling due within one year:
£
£
Corporation tax recoverable
746,733
709,747
Other debtors
132,792
135,022
879,525
844,769
LIFT BIOSCIENCES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 10 -
10
Creditors: amounts falling due within one year
2024
2023
£
£
Bank loans
10,000
10,000
Trade creditors
357,768
399,183
Amounts owed to group undertakings
61,820
Taxation and social security
52,028
Other creditors
106,176
4,283,252
587,792
4,692,435
Other creditors includes £Nil (2023: £4,264,034) in Simple Agreement for Future Equity (SAFE) notes issued to investors for monies received.
Also, included within other creditors is a finance lease liability of £22,465 (2023: £Nil) which is secured over the asset to which it relates.
11
Creditors: amounts falling due after more than one year
2024
2023
£
£
Bank loans
4,167
14,167
Other creditors
36,224
40,391
14,167
Included within other creditors falling due after more than one year is a finance lease liability of £36,224 (2023: £Nil) which is secured over the asset to which it relates.
12
Related party transactions
Included within creditors falling due within one year are balances of £61,820 (2023: £Nil) due from group companies.
During the year, a management charge of £20,866 (2023: £Nil) was incurred from a group company.
LIFT BIOSCIENCES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 11 -
13
Called up share capital
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of 1p each
13,787
13,787
138
138
2024
2023
2024
2023
Preference share capital
Number
Number
£
£
Issued and fully paid
Seed-1 Preferred shares of 1p each
608
608
6
6
Seed-2 Preferred shares of 1p each
10,536
10,536
105
105
Series A Preferred shares of 1p each
13,092
-
131
-
24,236
11,144
242
111
Preference shares classified as equity
242
111
Total equity share capital
380
249
During the year the company issued 13,092 1p Series A Preferred shares for total consideration of £10,198,786.
2024-12-312024-01-01falsefalsefalse20 February 2025CCH SoftwareCCH Accounts Production 2024.310No description of principal activityMr A W BlythMr P BurgermeisterM L PierceDr M GottardisBo Rode HansenDr A Rollet de Fougerolles2025-02-20092776382024-01-012024-12-31092776382024-12-31092776382023-12-3109277638core:OtherPropertyPlantEquipment2024-12-3109277638core:OtherPropertyPlantEquipment2023-12-3109277638core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3109277638core:CurrentFinancialInstrumentscore:WithinOneYear2023-12-3109277638core:ShareCapital2024-12-3109277638core:ShareCapital2023-12-3109277638core:SharePremium2024-12-3109277638core:SharePremium2023-12-3109277638core:RetainedEarningsAccumulatedLosses2024-12-3109277638core:RetainedEarningsAccumulatedLosses2023-12-3109277638core:ShareCapital2022-12-3109277638core:SharePremium2022-12-3109277638core:RetainedEarningsAccumulatedLosses2022-12-31092776382022-12-3109277638bus:Director12024-01-012024-12-3109277638core:RetainedEarningsAccumulatedLosses2023-01-012023-12-31092776382023-01-012023-12-3109277638core:RetainedEarningsAccumulatedLosses2024-01-012024-12-3109277638core:ShareCapital2024-01-012024-12-3109277638core:SharePremium2024-01-012024-12-3109277638core:IntangibleAssetsOtherThanGoodwill2024-01-012024-12-3109277638core:PatentsTrademarksLicencesConcessionsSimilar2024-01-012024-12-3109277638core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-01-012024-12-3109277638core:PlantMachinery2024-01-012024-12-3109277638core:FurnitureFittings2024-01-012024-12-3109277638core:PatentsTrademarksLicencesConcessionsSimilar2023-12-3109277638core:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-12-31092776382023-12-3109277638core:PatentsTrademarksLicencesConcessionsSimilar2024-12-3109277638core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-12-3109277638core:PatentsTrademarksLicencesConcessionsSimilarcore:ExternallyAcquiredIntangibleAssets2024-01-012024-12-3109277638core:DevelopmentCostsCapitalisedDevelopmentExpenditurecore:ExternallyAcquiredIntangibleAssets2024-01-012024-12-3109277638core:ExternallyAcquiredIntangibleAssets2024-01-012024-12-3109277638core:PatentsTrademarksLicencesConcessionsSimilar2023-12-3109277638core:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-12-3109277638core:OtherPropertyPlantEquipment2023-12-3109277638core:OtherPropertyPlantEquipment2024-01-012024-12-3109277638core:PlantMachinery2023-12-3109277638core:CurrentFinancialInstruments2024-12-3109277638core:CurrentFinancialInstruments2023-12-3109277638core:WithinOneYear2024-12-3109277638core:WithinOneYear2023-12-3109277638core:Non-currentFinancialInstruments2024-12-3109277638core:Non-currentFinancialInstruments2023-12-3109277638bus:PrivateLimitedCompanyLtd2024-01-012024-12-3109277638bus:FRS1022024-01-012024-12-3109277638bus:AuditExemptWithAccountantsReport2024-01-012024-12-3109277638bus:Director22024-01-012024-12-3109277638bus:Director32024-01-012024-12-3109277638bus:Director42024-01-012024-12-3109277638bus:Director52024-01-012024-12-3109277638bus:Director62024-01-012024-12-3109277638bus:SmallCompaniesRegimeForAccounts2024-01-012024-12-3109277638bus:FullAccounts2024-01-012024-12-31xbrli:purexbrli:sharesiso4217:GBP